摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苯基-2-(1,2,4-1H-三唑-1-基)乙酮盐酸盐 | 1092852-28-2

中文名称
1-苯基-2-(1,2,4-1H-三唑-1-基)乙酮盐酸盐
中文别名
——
英文名称
1-phenyl-2-(1,2,4-1H-triazol-1-yl)ethanone hydrochloride
英文别名
1-phenyl-2-[1,2,4]triazol-1-yl-ethanone hydrochloride;1-Phenyl-2-(1,2,4-triazol-1-yl)ethanone;hydrochloride
1-苯基-2-(1,2,4-1H-三唑-1-基)乙酮盐酸盐化学式
CAS
1092852-28-2
化学式
C10H9N3O*ClH
mdl
——
分子量
223.662
InChiKey
ACSZBUMBFVNTAN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.58
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    47.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    1-苯基-2-(1,2,4-1H-三唑-1-基)乙酮盐酸盐potassium carbonate 作用下, 以 为溶剂, 以100%的产率得到1-苯基-2-(1H-1,2,4-噻唑-1-基)乙酮
    参考文献:
    名称:
    Anti-Plasmodium activity of imidazolium and triazolium salts
    摘要:
    We have previously reported that tetrazolium salts were both potent and specific inhibitors of Plasmodium replication, and that they appear to interact with a parasite component that is both essential and conserved. The use of tetrazolium salts in vivo is limited by the potential reduction of the tetrazolium ring to form an inactive, neutral acyclic formazan. To address this issue imidazolium and triazolium salts were synthesized and evaluated as Plasmodium inhibitors. Many of the imidazolium and triazolium salts were highly potent with active concentrations in the nanomolar range in Plasmodium falciparum cultures, and specific to Plasmodium with highly favorable therapeutic ratios. The results corroborate our hypothesis that an electron-deficient core is required so that the compound may thereby interact with a negatively charged moiety on the parasite merozoite; the side groups in the compound then form favorable interactions with adjacent parasite components and thereby determine both the potency and selectivity of the compound. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.05.020
  • 作为产物:
    描述:
    参考文献:
    名称:
    1-芳基-2-(1H-咪唑-1-基/ 1H-1,2,4-三唑-1-基)乙酮及其衍生物对血红素加氧酶的抑制作用
    摘要:
    我们研究小组先前的研究一直与血红素加氧酶选择性抑制剂(HO-1和HO-2)的设计有关。其中大多数是基于吡咯(通常是咪唑)和芳族部分的四碳键合。在本研究中,我们设计和合成了一系列抑制候选物,这些抑制物在这些基团之间具有较短的连接,特别是一系列的1-芳基-2-(1 H-咪唑-1-基/ 1 H-1,2,4-三唑-1-基)乙酮及其衍生物。关于HO-1抑制,发现产生最佳结果的芳族部分是卤素取代的残基,例如3-溴苯基,4-溴苯基和3,4-二氯苯基,或烃基残基,例如2-萘基,4-联苯基。 ,4-苄基苯基和4-(2-苯乙基)苯基。在咪唑酮中,发现有五个(36 – 39和44)对两种同功酶非常有效(IC 50 < 5μM)。相对于咪唑酮类,该系列相应的三唑酮的显示四种化合物(54,55,61,和62)的选择性指数> 50,而对HO-1有利。对于唑二氧戊环,发现其中两个(分别为80和85)分别具有2-萘基部分
    DOI:
    10.1002/cmdc.201000120
点击查看最新优质反应信息

文献信息

  • TRIAZOLIUM AND IMIDAZOLIUM SALTS AND USES THEREOF
    申请人:Crandall Ian E.
    公开号:US20110257235A1
    公开(公告)日:2011-10-20
    The present disclosure relates to certain new and known triazolium and/or imidazolium salts and to their therapeutic use, for example in methods of treating or preventing an infection by a Plasmodium or Babesia parasite in a subject in need thereof. The triazolium and imidazolium salts are compounds of the Formula (I) or (II): wherein R 1 -R 4 , R 1′ -R 3′ , R 8 -R 11 , X, X′, X″, Y, Y′ and Y″ are as defined in the disclosure.
    本公开涉及某些新的和已知的三唑和/或咪唑盐及其治疗用途,例如在治疗或预防受需要的主体中由Plasmodium或Babesia寄生虫引起的感染的方法中。三唑和咪唑盐是以下化合物的化合物:其中R1-R4,R1′-R3′,R8-R11,X,X′,X″,Y,Y′和Y″如本公开所定义。
  • Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
    申请人:Gupta Ajay
    公开号:US20110319459A1
    公开(公告)日:2011-12-29
    Disclosed are compounds of the general formula (I): TC n D  (I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.
    本发明涉及一般式(I)的化合物:TCnD(I),包括单独使用或与其他化疗药物联合使用的有效量的该化合物的组合物,以及用于治疗或预防癌症和抑制肿瘤组织生长的有用方法。这些化合物减弱了与增加血红素氧合酶活性相关的氧化损伤,并可以减少转化细胞中的细胞增殖。此外,所述化合物和组合物可用作神经保护剂,并用于治疗或预防中枢神经系统的神经退行性疾病和其他疾病。
  • Heme Oxygenase Inhibition by 1-Aryl-2-(1H-imidazol-1-yl/1H-1,2,4-triazol-1-yl)ethanones and Their Derivatives
    作者:Gheorghe Roman、Jason Z. Vlahakis、Dragic Vukomanovic、Kanji Nakatsu、Walter A. Szarek
    DOI:10.1002/cmdc.201000120
    日期:2010.9.3
    been concerned with the design of selective inhibitors of heme oxygenases (HO‐1 and HO‐2). The majority of these were based on a four‐carbon linkage of an azole, usually an imidazole, and an aromatic moiety. In the present study, we designed and synthesized a series of inhibition candidates containing a shorter linkage between these groups, specifically, a series of 1‐aryl‐2‐(1H‐imidazol‐1‐yl/1H‐1
    我们研究小组先前的研究一直与血红素加氧酶选择性抑制剂(HO-1和HO-2)的设计有关。其中大多数是基于吡咯(通常是咪唑)和芳族部分的四碳键合。在本研究中,我们设计和合成了一系列抑制候选物,这些抑制物在这些基团之间具有较短的连接,特别是一系列的1-芳基-2-(1 H-咪唑-1-基/ 1 H-1,2,4-三唑-1-基)乙酮及其衍生物。关于HO-1抑制,发现产生最佳结果的芳族部分是卤素取代的残基,例如3-溴苯基,4-溴苯基和3,4-二氯苯基,或烃基残基,例如2-萘基,4-联苯基。 ,4-苄基苯基和4-(2-苯乙基)苯基。在咪唑酮中,发现有五个(36 – 39和44)对两种同功酶非常有效(IC 50 < 5μM)。相对于咪唑酮类,该系列相应的三唑酮的显示四种化合物(54,55,61,和62)的选择性指数> 50,而对HO-1有利。对于唑二氧戊环,发现其中两个(分别为80和85)分别具有2-萘基部分
  • Anti-Plasmodium activity of imidazolium and triazolium salts
    作者:Jason Z. Vlahakis、Carmen Lazar、Ian E. Crandall、Walter A. Szarek
    DOI:10.1016/j.bmc.2010.05.020
    日期:2010.8
    We have previously reported that tetrazolium salts were both potent and specific inhibitors of Plasmodium replication, and that they appear to interact with a parasite component that is both essential and conserved. The use of tetrazolium salts in vivo is limited by the potential reduction of the tetrazolium ring to form an inactive, neutral acyclic formazan. To address this issue imidazolium and triazolium salts were synthesized and evaluated as Plasmodium inhibitors. Many of the imidazolium and triazolium salts were highly potent with active concentrations in the nanomolar range in Plasmodium falciparum cultures, and specific to Plasmodium with highly favorable therapeutic ratios. The results corroborate our hypothesis that an electron-deficient core is required so that the compound may thereby interact with a negatively charged moiety on the parasite merozoite; the side groups in the compound then form favorable interactions with adjacent parasite components and thereby determine both the potency and selectivity of the compound. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多